This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
Stem Cell Research & Therapy Open Access 25 March 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Lanier LL . Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008; 9: 495–502.
Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727–729.
Nausch N, Cerwenka A . NKG2D ligands in tumor immunity. Oncogene 2008; 27: 5944–5958.
von Strandmann EP, Hansen HP, Reiners KS, Schnell R, Borchmann P, Merkert S et al. A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo. Blood 2006; 107: 1955–1962.
Weng WK, Levy R . Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940–3947.
van der Veer MS, de Weers M, van Kessel B, Bakker JM, Wittebol S, Parren PW et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 2010; 96: 284–290.
de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 2011; 186: 1840–1848.
Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999; 285: 730–732.
Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ . NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nat Immunol 2003; 4: 557–564.
Inagaki A, Ishida T, Yano H, Ishii T, Kusumoto S, Ito A et al. Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. Int J Cancer 2009; 125: 212–221.
Cho HM, Rosenblatt JD, Tolba K, Shin SJ, Shin DS, Calfa C et al. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response. Cancer Res 2010; 70: 10121–10130.
Acknowledgements
This study was supported by research Grant 2007.065.1 from the Wilhelm Sander Stiftung, Neustadt, Germany, research Grant DJCLS R 08/01 from the Deutsche José Carreras Leukämie Stiftung e.v., and intramural funding from the Christian-Albrechts-University Kiel. We thank Anja Muskulus, Britta von Below and Heidi Bosse for expert technical assistance. Sahar Mohseni Nodehi was supported by the FAZIT-Stiftung (Frankfurt am Main, Germany).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M de Weers, PWHI Parren and JGJ van de Winkel are employees of Genmab. The remaining authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Leukemia website
Supplementary information
Rights and permissions
About this article
Cite this article
Kellner, C., Hallack, D., Glorius, P. et al. Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. Leukemia 26, 830–834 (2012). https://doi.org/10.1038/leu.2011.288
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2011.288
This article is cited by
-
Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future
Stem Cell Research & Therapy (2021)
-
Targeting natural killer cells in cancer immunotherapy
Nature Immunology (2016)